An observational study in Heart Failure, sponsored by National Research Center for Preventive Medicine. Completed at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-15.
Sponsored by National Research Center for Preventive Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 96 studies in Heart Failure with a site in Russian Federation — 6 open to participants now, 7 under way, none of them phase 3. Heart Failure · Russian Federation.
Among the 96 studies in Heart Failure with a site in Russian Federation, this one is the 18th largest by enrollment of the 19 observational ones that give a count, is one of 9 that started in 2019, is one of 19 observational ones, and was the 73rd registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →6 of the 96 studies in Heart Failure with a site in Russian Federation are open now. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russian Federation
Ages 60–74 · Women only
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russian Federation
Ages 18–80
Population Health Research Institute · Sites in Russian Federation, Brazil, Canada
Closed Joint-Stock Company NeoCor · Sites in Russian Federation
Ages 60–70
I.M. Sechenov First Moscow State Medical University · Sites in Russian Federation
Ages 40+
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
96 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 22 · Phase 3 31 · Phase 4 7
First in 2002; this study’s year is marked. 9 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 200 across 1,987 observational studies indexed under Heart Failure.
Median enrollment 398 across the 77 interventional studies, 400 across the 19 observational. Of the 80 that completed or were terminated, 43 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 96 have an industry lead sponsor. The 10 most frequent:
National Research Center for Preventive Medicine is the lead sponsor of 18 studies on the registry; none are open to participants now.
National Research Center for Preventive Medicine has 2 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 96 studies in Heart Failure with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this prospective cohort study is to assess the adherenсe to medical therapy and its influence on long-term outcomes in patients with chronic heart failure in the outpatient registry
Registry PROFILE is a patients database with cardiovascular diseases who consistently apply to the specialized cardiology department of the "National Medical Research Center for Preventive Medicine" for consultation or to assess their possible participation in clinical trials The purpose of this study is to assess adherence to medical therapy and its impact on long-term outcomes in patients with chronic heart failure enrolled to PROFILE registry from 01 January 2016 to 01 July 2020. The patients who were enrolled between 01 January 2016 to 01 December 2019 will be invited to clinical visit by phone. For patients who will join PROFILE registry after 01 December 2019 the first visit of this study is the day of enrollment to PROFILE registry.
The first visit (V1) is an inclusion in the study. During this visit assess adherence to medication therapy General and to specific medications. The main factors affecting treatment adherence will be identified.
The second visit (V2) is planned for each patient 1 year after the first visit (V2). During the second visit the adherence to the therapy and frequency of Secondary Outcome Measures will be estimated. Impossible to visit repeated, a telephone interview can be done
All patients with documented HF having consequentially come for consultation to the specialized cardiology department of the scientific research center from Junuary 1, 2016 to July 31, 2020 (Included in the registry PROFILE)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adherence to life-modifying treatment
The Adherence scale of the Russian National Society of evidence based pharmacotherapy will be used to assess patients' adherence to treatment. The patients will be asked questions about taking prescribed medications as recommended by a doctor. The score system with the min value in the scale 0 and the max value 4 is used for the assessment of the results: 0 - adherent, 1-2 - partially adherent, 3 - partially non-adherent, 4 - non adherent.
Time frame: 1 year
Death
Total number - of all events
Time frame: 1 year
Chronic heart failure decompensation with hospitalization
Total number - of all events
Time frame: 1 year
Chronic heart failure decompensation without hospitalization
- onset of new symptoms (example:. Cardiac asthma, orthopnea- if you haven't registered before); -- increase in NYHA ≥1;- increase dose of diuretic
Time frame: 1 year
Myocardial Infarction
Total number - of all events
Time frame: 1 year
Unplanned hospitalization for Cardiovascular disease
Total number - of all events
Time frame: 1 year
Plan to share: No
Ran from Dec 2019 to primary completion in Dec 2020, 12 months.
Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's 12 months is below that.
Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Research Center for Preventive Medicine